Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of brain or spine diseases in patients of Chinese origin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Chinese origin, with known or suspected brain or spine diseases

Exclusion Criteria:

• Pregnancy

• Lactation

• Conditions interfering with MRI

• Allergy to any contrast agent or any drugs

• Participation in other trial

• Require emergency treatment

• Severely impaired liver and kidney functions